ON THE SUBJECT OF LAB TEST MARKET PRICE REPORTING as required under PAMA, many clinical laboratory executives, pathologists, and industry experts see deep flaws in the process the federal Centers for Medicare & Medicaid Services has established. Yet, CMS itself seems blind to these flaws. Fortunately, the clinical lab executives are not alone. The Office […]
- OIG PAMA Update
OIG Comments on PAMA Plan and Exclusion of Many Labs from Reporting
Inspector general says results will be skewed because CMS won’t require data from certain labs
- By Joseph Burns
- > From the Volume XXIII No. 16 - November 28, 2016 Issue
- Tags: all lab tests, clfs, clinical lab, clinical lab test, clinical laboratories, Clinical Laboratory, clinical laboratory test, clinical laboratory tests, clinical labs, hospital laboratories, lab administrator, lab executive, lab industry, lab test, lab test prices, lab testing, lab tests, laboratories, laboratory executive, laboratory test, laboratory tests, Medicare, Medicare Part B, molecular pathology, pathologists, pathology test, private payer, Protecting Access to Medicare Act (PAMA), the clinical laboratory
